Shield Therapeutics CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactice to share its released an unaudited Q3 2024 trading update revealing $7.2 million in net revenues from ACCRUFeR prescriptions, with an average net selling price of $167 per prescription. Excluding July's summer buying trends, the NSP averaged $192 in Q3, and Shield anticipates maintaining this level into Q4.
Shield looks to gain traction, especially in the United States, where it partners with Viatris, deploying a sales force of 100 to promote ACCRUFeR. To support its objective of achieving cash flow positivity by 2025, Shield has expanded its working capital financing with Sallyport Commercial Finance from $10 million to $15 million. Additionally, Shanbhag also noted that steps are being taken to improve Shield’s cash position, including a planned 10% cost reduction and expanded financing from Sallyport, which he believes will support Shield’s objective of reaching cash flow positivity by the end of 2025.